Affordable Access

deepdyve-link
Publisher Website

SFPH proteins as therapeutic targets for a myriad of diseases

Authors
  • Wang, Dong1
  • Tabti, Redouane2
  • Elderwish, Sabria2
  • Djehal, Amel3
  • Chouha, Nora4
  • Pinot, Franck5
  • Yu, Peng1
  • Nebigil, Canan G.2
  • Désaubry, Laurent1, 2
  • 1 Sino-French Joint Lab of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science and Technology, Tianjin, China
  • 2 INSERM-University of Strasbourg, Regenerative Nanomedicine Laboratory (UMR1260), Faculty of Medicine, FMTS, Strasbourg, France
  • 3 Superior National School Biotechnology Taoufik Khaznadar, Constantine, Algeria
  • 4 University of Batna 2, Faculty of Biology, Batna, Algeria
  • 5 University of Strasbourg, CNRS, IBMP UPR 2357, Strasbourg, France
Type
Published Article
Journal
Bioorganic & medicinal chemistry letters
Publication Date
Oct 06, 2020
Volume
30
Issue
22
Pages
127600–127600
Identifiers
DOI: 10.1016/j.bmcl.2020.127600
PMID: 33035678
PMCID: PMC7536521
Source
PubMed Central
Keywords
Disciplines
  • Digest
License
Unknown

Abstract

The stomatin/prohibitin/flotillin/HflK/HflC (SPFH) domain is present in an evolutionarily conserved family of proteins that regulate a myriad of signaling pathways in archaea, bacteria and eukaryotes. The most studied SPFH proteins, prohibitins, have already been targeted by different families of small molecules to induce anticancer, cardioprotective, anti-inflammatory, antiviral, and antiosteoporotic activities. Ligands of other SPFH proteins have also been identified and shown to act as anesthetics, anti-allodynia, anticancer, and anti-inflammatory agents. These findings indicate that modulators of human or bacterial SPFH proteins can be developed to treat a wide variety of human disorders.

Report this publication

Statistics

Seen <100 times